Medicine
Doryx MPC 60 mg delayed-release tablet
Doryx MPC 60 mg delayed-release tablet is a prescription medicine containing Doxycycline for oral use, marketed by Mayne Pharma Commercial, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25° C (77° F), excursions permitted to 15°C to 30° C (59°F to 86° F).
Key facts
- Active ingredient (INN)
- Doxycycline
- Brand
- Doryx MPC
- Strength
- 60 mg
- Dosage form
- Delayed-release tablet
- Route
- Oral
- Packs
- 1 bottle, 60 tablets
- Marketing authorisation holder
- Mayne Pharma Commercial
- Manufacturer
- Mayne Pharma Commercial
- Origin register
- US FDA, United States
- Storage
- Store at 25° C (77° F), excursions permitted to 15°C to 30° C (59°F to 86° F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A01AB22 Doxycycline
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 2 January 2023
- Identifiers
- RxCUI 1801138, 1801140, 1801142 +1DailyMed set ID f9277bb8-982d-444d-9325-35d5c53a2d35NDC 51862-560Application NDA050795
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle in 1 carton / 6 tablet, delayed release in 1 bottle | 51862-560-00 | Mayne Pharma Commercial | 2 January 2023 |
| 60 tablet, delayed release in 1 bottle | 51862-560-60 | Mayne Pharma Commercial | 13 May 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 5 December 1967 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Doxycycline
Clinical summary
Doxycycline is a tetracycline-class drug indicated for the treatment of infections, among other approved uses. It is available as capsules, tablets and powder for injection for oral and intravenous use. MedsAcross supplies Doxycycline for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DoxycyclineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Doxycycline prescribing information (Wellhouse Pharma) · U.S. National Library of Medicine, DailyMed
Need Doryx MPC 60 mg delayed-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.